
E the and the Fr the

Hall King Hall II has a ser gen

Please type a plus sign (+) inside this box +

Attorney Docket P1468R1D1 **PATENT**



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION Assistant Commissioner of Patents Washington, D.C. 20231

NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

Avi J. Ashkenazi Anan Chuntharapai K. Jin Kim

pages of claims page(s) of abstract sheet(s) of drawings [x] formal [] informal

Title:

METHOD FOR MAKING MONOCLONAL ANTIBODIES AND CROSS-REACTIVE ANTIBODIES OBTAINABLE BY THE METHOD

1.	Type of Application				
[]	This application is for an original, non-provisional application.				
[]	This is a non-provisional application claiming priority to provisional application no, the entire disclosure of which is hereby incorporated by reference.				
[x]	This is a [] continuation-in-part [] continuation [x] divisional application claiming priority to application Serial Number 09/329,633, filed June 10, 1999, the entire disclosure of which is hereby incorporated by reference.				
2.	Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b) (Non-provisional)				

3.	Declaration or Oath				
	(for new and CIP applications; also for Cont./Div. where inventor(s) are being added) An executed declaration of the inventor(s) [] is enclosed [] will follow.				
	(for Cont./Div. where inventorship is the same or inventor(s) being deleted) _x A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).				
	(for Cont./Div. where inventor(s) being deleted) A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).				
4 .	Assignment				
	(for new and CIP applications) An Assignment of the invention to GENENTECH, INC. [] is enclosed with attached Recordation Form Cover Sheet [] will follow.				
	(for cont./div.) x The prior application is assigned of record to Genentech, Inc.				
5.	Amendments (for continuation and divisional applications)				
	Cancel in this application original claims of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)				
	A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)				
	Relate Back 35 U.S.C. 120 or 35 U.S.C. 119				
	Amend the specification by inserting before the first line the sentence:				
	This is a				
	non-provisional application continuation divisional continuation-in-part				
	of co-pending application(s)				
	Serial No. <u>09/329,633</u> filed on <u>June 10, 1999</u> , which application(s) is(are) incorporated herein by reference and to which application(s) priority is claimed under 35 USC §120				

International Application _ filed on _ which designated the U.S., which application(s) is(are) incorporated herein by reference and to which application(s) priority is claimed under 35 USC

§120					
 provisional application No filed _, the entire disclosure of which is hereby incorporated by					
reference and to which application(s) priority is claimed under 35 USC §119					

6. Fee Calculation (37 CFR 1.16)

The fee has been calculated as follows:

		CLAIN	IS FOR FEE CA	LCULATION	
Number Filed		Number Extra		Rate	Basic Fee 37 CFR 1:16(a) \$710.00
Total Claims	21	- 20 =	1	X \$18.00	\$18.00
Independent Claims	2	- 3=	0	X \$80.00	\$0.00
Multiple dependent claim(s), if any			+ \$270.00	\$0.00	
			ing Fee Calculation	\$728.00	

7. Method of Payment of Fees

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$728.00. A duplicate copy of this transmittal is enclosed.

8. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. <u>A duplicate copy of this sheet is enclosed</u>.

9. Additional Papers Enclosed

- [x] Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449
- [x] Submission of "Sequence Listing", Letter and Request to use Computer-Readable Sequence Listing under 37 CFR 1.1821(e)
- [] A new Power of Attorney or authorization of agent. Other: Nonpublication Request under 35 USC 122(b)(2)(B)(i)

10. Maintenance of Copendency of Prior Application (for continuation and divisional applications)

[This item **must** be completed and the necessary papers filed in the prior application if the period set in the prior application has run]

<u> </u>	A petition, fee and/or response has been filed to extend the term in the pending prior application until
	A copy of the petition for extension of time in the <i>prior</i> application is attached.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Avi J. Ashkenazi et al.

Serial No.: not yet assigned

Filed: April 9, 2001

For: METHOD FOR MAKING

MONOCLONAL ANTIBODIES AND CROSS-REACTIVE ANTIBODIES OBTAINABLE BY THE METHOD

Group Art Unit: not yet assigned

Examiner: not yet assigned

EXPRESS MAIL LABEL NO. EL 599 5841 98 US

Letter and REQUEST TO USE COMPUTER-READABLE SEQUENCE LISTING

UNDER 37 CFR §1.821(e)

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

Applicants respectfully request that the compliant computer-readable Sequence Listing filed in application Serial No. 09/329,633 be used as the computer-readable Sequence Listing for the present, above-identified application.

The paper copy of the <u>Sequence Listing filed</u> in the present application is identical to the computer-readable copy of the Sequence Listing filed in the application Serial No. 09/329,633.

Respectfully submitted,

GENENTECH, INC.

Date: April 9, 2001

Wendy M. Lee Reg. No. 40,378

Telephone No. (650) 225-1994

09157
PATENT TRADEMARK OFFICE

11. Correspondence Address:

X Address all future communications to:

Attn: Wendy M. Lee

Respectfully submitted, GENENTECH, INC.

Date: April 9, 2001

By: // Wendy M. Lee

Reg. No. 40,378

Telephone No. (650) 225-1994

09157

PATENT TRADEMARK OFFICE